The non-invasive prenatal testing market in US, which is extremely lucrative and a growing segment of the diagnostics industry, is driven by companies developing and offering these tests. The average age of women giving birth in United States has increased over the years. It’s no longer unusual for women to have a first child at age 35 or even 40. This trend has been attributed to numerous factors such as recession and associated affordability issues, and women being more focused on their careers than before. However, increased age of the mother also increases the risk of her child developing chromosomal abnormalities. This risk has thus paved the way for NIPT tests which have emerged as the next big thing in the field of prenatal diagnostics.
According to our report “US Non-Invasive Prenatal Testing Market Outlook 2020”, the rise in high risk births has been contributing to the growth of the NIPT market which is anticipated to witness an impressive double digit growth in the next few years. Our report provides a detailed insight into the current scenario and future outlook of the US NIPT market. It has been inferred that most of the total market remains untapped. Contribution of every NIPT player has also been provided in terms of current and future market shares.
The demographic scenario of United States has been discussed with focus on the current and future number of births, with the demographics segregated by age and state. Although the market has witnessed stupendous growth and new tests have gained acceptance rapidly, much of it still remains untapped due to various reasons. This has been discussed in the section dedicated to the potential market for 2014 and 2020.
A thorough analysis too has been done illustrating the views of regulatory authorities, players and consumers towards regulatory stringency and the direction of regulations in the future have also been covered.
Research and innovation in this field is at its peak, and market players are conducting validation studies to check the level of specificity and sensitivity while comparing clinical tests. Already several clinical trials in the pipeline upon completion may impact the overall market in a significant manner.
The US NIPT sector is characterized by the presence of players like Sequenom, Verinata, Ariosa and Natera. These players have been profiled with their strengths and weaknesses and latest developments in the field of NIPT. The report provides a prudent analysis of the current and future size of the market weighing the possible pessimistic and optimistic scenarios and is a must buy for players planning to enter the prenatal segment.